Peak Bio, Inc. (PKBOW) Financial Analysis & Valuation | Quarter Chart
Peak Bio, Inc. (PKBOW)
PKBOWPrice: $0.01
Fair Value: 🔒
🔒score
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ... more
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addre... more
Description
Shares
| Market Cap | $531,873 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Hoyoung Huh |
| IPO Date | 2022-11-02 | CAGR | — |
| Employees | 6 | Website | peak-bio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PKBOW chart loading...
Fundamentals
Technicals
| Enterprise Value | $3,263 | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | -0.16 |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | 0.02% | ROA | -0.22% |
| ROCE | 0.14% | Current Ratio | 0.07 |
| Quick Ratio | 0.07 | Cash Ratio | 0.04 |
| Debt/Equity | -0.35 | Interest Coverage | -1.61 |
| Altman Z Score | -52.03 | Piotroski Score | 2 |